The design of small-molecule prodrugs and activatable phototherapeutics for cancer therapy

HH Han, HM Wang, P Jangili, M Li, L Wu… - Chemical Society …, 2023‏ - pubs.rsc.org
Cancer remains as one of the most significant health problems, with approximately 19
million people diagnosed worldwide each year. Chemotherapy is a routinely used method to …

The intracellular and extracellular microenvironment of tumor site: the trigger of stimuli‐responsive drug delivery systems

X **g, H Hu, Y Sun, B Yu, H Cong, Y Shen - Small Methods, 2022‏ - Wiley Online Library
The tumor microenvironment (TME), including intracellular and extracellular
microenvironment, contains many biochemical indicators (such as acidity/alkalinity, oxygen …

[HTML][HTML] Biomedical applications of MnO2 nanomaterials as nanozyme-based theranostics

S Sisakhtnezhad, M Rahimi, S Mohammadi - Biomedicine & …, 2023‏ - Elsevier
Abstract Manganese dioxide (MnO 2) nanoenzymes/nanozymes (MnO 2-NEs) are 1–100
nm nanomaterials that mimic catalytic, oxidative, peroxidase, and superoxide dismutase …

Recent progress in stimuli-responsive polymeric micelles for targeted delivery of functional nanoparticles

Z Cao, X Zuo, X Liu, G Xu, KT Yong - Advances in Colloid and Interface …, 2024‏ - Elsevier
Stimuli-responsive polymeric micelles have emerged as a revolutionary approach for
enhancing the in vivo stability, biocompatibility, and targeted delivery of functional …

Photoswitchable molecules in long-wavelength light-responsive drug delivery: from molecular design to applications

S Jia, WK Fong, B Graham, BJ Boyd - Chemistry of Materials, 2018‏ - ACS Publications
Stimuli-responsive nanocarriers can release their bioactive cargo “on demand”, potentially
improving the selectivity, specificity, and efficacy of therapeutic drugs. Light of wavelengths …

Development of hypoxia-activated PROTAC exerting a more potent effect in tumor hypoxia than in normoxia

W Cheng, S Li, X Wen, S Han, S Wang, H Wei… - Chemical …, 2021‏ - pubs.rsc.org
Hypoxia is a hallmark of many solid tumors, and it causes the overexpression of a variety of
proteins including the epidermal growth factor receptor (EGFR). Many antitumor prodrugs …

[HTML][HTML] Hypoxia-inducible factor in cancer: from pathway regulation to therapeutic opportunity

BM Ortmann - BMJ oncology, 2024‏ - pmc.ncbi.nlm.nih.gov
Cancer remains one of the most formidable challenges in modern medicine, due to its
complex and dynamic nature, which demands innovative therapeutic approaches. One …

[HTML][HTML] Delivery of therapeutic oligonucleotides in nanoscale

L Wu, W Zhou, L Lin, A Chen, J Feng, X Qu, H Zhang… - Bioactive materials, 2022‏ - Elsevier
Therapeutic oligonucleotides (TOs) represent one of the most promising drug candidates in
the targeted cancer treatment due to their high specificity and capability of modulating …

Recent advances in nanoparticle-based targeted drug-delivery systems against cancer and role of tumor microenvironment

UA Ashfaq, M Riaz, E Yasmeen… - Critical Reviews™ in …, 2017‏ - dl.begellhouse.com
Cancer is one of the major causes of death worldwide. The silent activation of cellular factors
responsible for deviation from normal regulatory pathways leads to the development of …

Hypoxia-responsive nanoparticles for tumor-targeted drug delivery

Y Li, J Jeon, JH Park - Cancer Letters, 2020‏ - Elsevier
Hypoxia is a negative prognostic indicator of solid tumors. Increasing evidence indicates that
the intratumoral hypoxic microenvironment is strongly related to enhanced tumor …